Immunocore Holdings plc (NASDAQ:IMCR) Given Consensus Recommendation of “Moderate Buy” by Analysts

Shares of Immunocore Holdings plc (NASDAQ:IMCR) have earned a consensus rating of “Moderate Buy” from the twelve brokerages that are presently covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a hold recommendation and eleven have given a buy recommendation to the company. The average 12 month price objective among brokerages that have issued a report on the stock in the last year is $80.40.

A number of equities analysts have commented on IMCR shares. HC Wainwright restated a “buy” rating and set a $100.00 price objective on shares of Immunocore in a research report on Tuesday, September 17th. Cantor Fitzgerald restated an “overweight” rating on shares of Immunocore in a research report on Monday, September 9th. Needham & Company LLC cut their price objective on shares of Immunocore from $81.00 to $78.00 and set a “buy” rating for the company in a research report on Tuesday, September 17th. Oppenheimer restated an “outperform” rating and set a $89.00 price objective (up previously from $87.00) on shares of Immunocore in a research report on Friday, August 9th. Finally, JPMorgan Chase & Co. cut their price objective on shares of Immunocore from $70.00 to $66.00 and set an “overweight” rating for the company in a research report on Wednesday, July 10th.

Hedge Funds Weigh In On Immunocore

Large investors have recently made changes to their positions in the stock. Hsbc Holdings PLC purchased a new position in Immunocore during the 4th quarter valued at about $4,450,000. TD Asset Management Inc increased its holdings in Immunocore by 14.9% during the 4th quarter. TD Asset Management Inc now owns 346,930 shares of the company’s stock valued at $23,702,000 after acquiring an additional 45,010 shares in the last quarter. NEOS Investment Management LLC purchased a new position in Immunocore during the 4th quarter valued at about $262,000. Oppenheimer & Co. Inc. purchased a new position in Immunocore during the 4th quarter valued at about $1,314,000. Finally, Bellevue Group AG increased its holdings in Immunocore by 4,817.1% during the 4th quarter. Bellevue Group AG now owns 976,054 shares of the company’s stock valued at $66,684,000 after acquiring an additional 956,204 shares in the last quarter. Hedge funds and other institutional investors own 84.50% of the company’s stock.

Immunocore Stock Up 0.3 %

Shares of NASDAQ:IMCR opened at $31.21 on Friday. The stock has a market cap of $1.56 billion, a P/E ratio of -25.58 and a beta of 0.73. The firm has a fifty day moving average price of $35.62 and a 200 day moving average price of $44.75. The company has a debt-to-equity ratio of 1.31, a current ratio of 5.17 and a quick ratio of 5.15. Immunocore has a 1-year low of $29.76 and a 1-year high of $76.98.

Immunocore (NASDAQ:IMCR) last issued its quarterly earnings results on Thursday, August 8th. The company reported ($0.23) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.48) by $0.25. The firm had revenue of $75.40 million during the quarter, compared to analysts’ expectations of $74.58 million. Immunocore had a negative net margin of 19.16% and a negative return on equity of 14.68%. Immunocore’s quarterly revenue was up 26.2% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.37) EPS. Sell-side analysts predict that Immunocore will post -1.79 EPS for the current year.

Immunocore Company Profile

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.